CYP2C19 polymorphism and proton pump inhibitors (Q35831792)

10 August 2017

1 reference

title

CYP2C19 polymorphism and proton pump inhibitors (English)

1 reference

10 August 2017

Ulrich Klotz

1

1 reference

10 August 2017

Matthias Schwab

series ordinal

2

1 reference

10 August 2017

Gerhard Treiber

series ordinal

3

1 reference

10 August 2017

publication date

1 July 2004

1 reference

Basic and Clinical Pharmacology and Toxicology

10 August 2017

published in

1 reference

10 August 2017

volume

95

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

2-8

1 reference

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Pharmacogenetics of the proton pump inhibitors: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Genetics of response to proton pump inhibitor therapy: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Problems associated with the clinical use of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Pharmacogenetics and clinical gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Drug interactions. Mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Cytochrome P450 enzyme polymorphisms and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.2004.PTO950102.X

10.1111/J.1600-0773.2004.PTO950102.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference